Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0769 • ACR Convergence 2023
Development and Validation of a Combined Clinical and Genetic Risk Score for Interstitial Lung Disease in a Large, Multicenter, Prospective Rheumatoid Arthritis Cohort
Austin Wheeler¹, Joshua Baker², Yangyuna Yang¹, Punyasha Roul¹, K Wysham³, Grant Cannon⁴, Gary Kunkel⁵, Gail Kerr⁶, Dana Ascherman⁷, Paul Monach⁸, Andreas Reimold⁹, Jill Poole¹, Tony Merriman¹⁰, Ted R Mikuls¹¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Texas Southwestern Medical Center, Dallas, TX, ¹⁰University of Alabama at Birmingham, Birmingham, AL, ¹¹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA that causes substantial morbidity and mortality. Although some clinical and genetic risk…
Abstract Number: 0808 • ACR Convergence 2023
Real-World Disease Monitoring Patterns in Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Veterans Affairs Health Care System
Bryant England¹, Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul¹, Daniel Hershberger¹, Brian Sauer², Grant Cannon³, Joshua Baker⁴ and Ted R Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: There are currently no clinical practice guidelines for monitoring RA-associated interstitial lung disease (RA-ILD). Pulmonary function tests (PFTs) and chest computed tomography (CT) imaging…
Abstract Number: 0976 • ACR Convergence 2023
Sarcopenia and All-Cause Mortality in US Adults with and Without Rheumatoid Arthritis
Qiping Xu and Xuanling Du, Mayo Clinic Health System, Mankato, MN
Background/Purpose: Sarcopenia, which refers to the loss of muscle strength and mass, has been linked to adverse health outcomes. Although several systemic reviews have reported…
Abstract Number: 1022 • ACR Convergence 2023
Lower Rates of Statin Therapy Initiation in Dermatomyositis/Polymyositis vs. Rheumatoid Arthritis Patients with Hyperlipidemia: A Multicenter USA-Based Study (2018-2023)
Joseph Fares¹, ross Summer¹ and Giorgos Loizidis², ¹The Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University Hospital, Philadelphia, PA, ²Division of Rheumatology, Thomas Jefferson University Hospital, Philadelphia, PA
Background/Purpose: Despite the proven cardioprotective benefits of statin therapy in RA, concern for statin-associated muscle symptoms (SAMS) might deter clinicians from prescribing them to DM/PM…
Abstract Number: 1260 • ACR Convergence 2023
Optimal Approaches for Reducing Depressive Symptoms in Rheumatoid Arthritis Patients Based on Psychological Interventions: A Systematic Review and Network Meta-analysis
Zhang Lijuan and Wu Beiwen, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: In recent years, numerous psychological interventions for rheumatoid arthritis (RA) patients have been developed. However, it remains unclear which psychological interventions are effective and…
Abstract Number: 1278 • ACR Convergence 2023
Nature and Severity of Activity Limitations According to the Health Assessment Questionnaire Disability Index in Patients with Rheumatoid Arthritis and Functional Disability
Manja van Wissen¹, Maaike gademan¹, Cornelia van den Ende², Max Teuwen¹, Wilfred Peter¹, Dirkjan van Schaardenburg³, Alfons den Broeder², Thea Vliet Vlieland⁴ and Salima van Weely¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Reade, Amsterdam, Netherlands, ⁴Leids University Medical Center, Leiden, Netherlands
Background/Purpose: Not withstanding modern treatment, some Rheumatoid Arthritis (RA) patients have severe disability due to persistently high disease activity, joint destruction/deformities and/or comorbidities. Insight into…
Abstract Number: 1294 • ACR Convergence 2023
Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Using Rasch Measurement Theory and Cognitive Interviewing to Achieve More Meaningful Measurement
Tim Pickles¹, Mike Horton², Karl Bang Christensen³, Rhiannon Phillips⁴, David Gillespie¹, Neil Mo⁵ and Ernest Choy⁶, ¹Cardiff University, Cardiff, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Copenhagen, Copenhagen, Denmark, ⁴Cardiff Metropolitan University, Cardiff, United Kingdom, ⁵Swansea Bay University Health Board, Port Talbot, United Kingdom, ⁶Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Disease Activity (DA) monitoring is a standard of care in Rheumatoid Arthritis (RA). A systematic review of Patient Reported Outcome Measures (PROMs) for RA…
Abstract Number: 1310 • ACR Convergence 2023
Comparison of Two Methotrexate Initiation Strategies in Rheumatoid Arthritis in Current Practice
Paola Vidal-Montal¹, Alice Combier², Alexia STEELANDT², Marion THOMAS², Javier Narvaez³, Joan Miquel Nolla¹, Yannick ALLANORE⁴ and Jerome AVOUAC⁵, ¹Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Université Paris Cité, Paris, France, ⁵Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: To compare the efficacy and tolerance at 3 and 6 months of two methotrexate (MTX) initiation strategies in rheumatoid arthritis (RA). Methods: Retrospective,monocentric,cross-sectionalstudy including…
Abstract Number: 1328 • ACR Convergence 2023
Switching Biologics or Janus Kinase Inhibitors Is Effective in Difficult-to-treat Rheumatoid Arthritis, Regardless of Inflammation
Katsuaki Onishi¹, Yutaro Yamada², Tadashi Okano², Kenji Mamoto², Shohei Anno³, Tatsuya Koike⁴ and Hiroaki Nakamura², ¹Baba Memorial Hospital, Osaka, Japan, ²Osaka Metropolitan University, Osaka, Japan, ³Yodogawa Christian Hospital, Osaka, Japan, ⁴Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan
Background/Purpose: Although biologics (BIO) or Janus kinase inhibitors (JAKi) have improved treatment for rheumatoid arthritis (RA), there are patients with difficult disease activity control even…
Abstract Number: 1344 • ACR Convergence 2023
Efficacy and Safety of JAK Inhibitors in Difficult to Treat Rheumatoid Arthritis in Clinical Practice
Omar AL TABAA¹, Sophie HECQUET², Marion THOMAS³, Sandrine CARVES¹, Alice Combier¹, Corinne MICELI⁴, Olivier Fogel³, Anna Molto³, Yannick ALLANORE⁵ and Jerome AVOUAC⁶, ¹APHP / Cochin Hospital, Paris, France, ²APHP / Cochin Hospital / Paris University, Paris, France, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Université de Paris Cité, HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁵Université Paris Cité, Paris, France, ⁶Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Use of JAK inhibitors (JAKi) may be challenged in difficult to treat rheumatoid arthritis (D2TRA) by the multiplicity of previous treatment lines and the…
Abstract Number: 1659 • ACR Convergence 2023
Cellular Deconstruction of Stromal and Myeloid Cell Compartments in the Inflamed Synovium of Juvenile Idiopathic Arthritis
Christopher Mahony¹, Chrissy Bolton², Charlotte Smith¹, Vicky Alexiou³, Huong Nguyen³, Patricia Reis-Nisa¹, Søren Lomholt⁴, Annie Hackland¹, Sunit Davda⁵, Sugrah Sultan⁶, Charlene Foley⁵, Catherine Cotter⁶, Klaudia Kupiec³, Calliope Dendrou², Elizabeth C Rosser⁷, Accelerating Medicines Partnership (AMP): RA/SLE⁸, Fan Zhang⁹, Soumya Raychaudhuri⁸, Michael Brenner¹⁰, Christopher Buckley², Manigandan Thyagarajan⁶, Accelerating Medicines Partnership Program RA SLE Network¹¹, Zishan Shiekh⁶, Sandrine Compeyrot-Lacassagne⁵, Samantha Chippington⁵, Mark Coles², Eslam Al-Abadi⁶, Andrew Filer¹, Tissue Research in Childhood Onset Inflammatory Arthritis (TRICIA) Consortium¹², Lucy R Wedderburn³ and Adam Croft¹, ¹University of Birmingham, Birmingham, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³UCL Great Ormond Street Institute of Child Health, London, United Kingdom, ⁴Aarhus University, Aarhus, Denmark, ⁵Great Ormond Street Hospital, London, United Kingdom, ⁶Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom, ⁷University College London, London, United Kingdom, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Colorado, Aurora, CO, ¹⁰Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²MRC, Birmingham, United Kingdom
Background/Purpose: The synovial membrane is the primary target tissue during the effector phase of inflammatory arthritis in children and young people with Juvenile Idiopathic Arthritis…
Abstract Number: 1729 • ACR Convergence 2023
An Antibody-drug Conjugate of Anti-TNFα Antibody and a Novel Glucocorticoid Molecule Exerts Synergistic Anti-inflammatory Effects for Treatment of Autoimmune Diseases
Yuhao Qin¹, Wenming Ren², Liangqin Tong³, lu su³ and cheng liao³, ¹Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China, ²Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pudong New District, China, ³Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China
Background/Purpose: Tumor necrosis factor α (TNFα) is a pivotal pro-inflammatory cytokine. And TNF inhibitors are the most successful anti-rheumatic drugs for the treatment of autoimmune…
Abstract Number: 1745 • ACR Convergence 2023
Chronic Inflammation and Collagen IV Fragment Canstatin Influence Rheumatoid Arthritis Synovial Fibroblast and Endothelial Cell Interactions in Vitro and in Vivo
Corinna Heck¹, Sophie Haun¹, Daria Kürsammer¹, Klaus Frommer¹, Mona Arnold¹, Markus Rickert², Katrin Susanne Lips³, Stefan Rehart⁴, Ulf Müller-Ladner¹ and Elena Neumann¹, ¹Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ²Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, ³Justus Liebig University Gießen, Department of Experimental Trauma Surgery, Giessen, Germany, ⁴Dept. of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital Frankfurt, Frankfurt, Germany
Background/Purpose: In the inflamed synovium of RA patients, increased and altered angiogenesis is a pathological feature. Key players are chronically activated RA synovial fibroblasts (RASF),…
Abstract Number: 1761 • ACR Convergence 2023
JAK/STAT Inhibition Modifies the Innate Lymphoid Cells 1 Immune Response in Patients with Rheumatoid Arthritis
Lidia La Barbera¹, Marianna Lo Pizzo¹, Chiara Rizzo¹, Leila Mohammadnezhad¹, federica Camarda¹, Francesco Ciccia² and Giuliana Guggino¹, ¹University of Palermo, Palermo, Italy, ²University of Campania - Luigi Vanvitelli, Naples, Italy
Background/Purpose: Recent evidence suggests that innate lymphoid cells (ILCs) might be involved in rheumatoid arthritis (RA) pathogenesis and individuals at risk of RA exhibited an…
Abstract Number: 1821 • ACR Convergence 2023
The “Weekend Effect” and Rheumatological Association in Patients with Diffuse Alveolar Haemorrhage
Shobhit Piplani¹, Shreya Gulati², Vladimir Jelic¹, Asad Ahmed³, Sung Mi Yoon¹, Donclair Brown¹, Miroslav Radulovic¹ and Beverly Johnson⁴, ¹Jacobi Medical Center/North Central Bronx, Albert Einstein College of Medicine, NYC Health and Hospitals, Bronx, NY, ²Jawahar lal Nehru Medical College, New York, NY, ³SUNY Downstate, Brooklyn, NY, ⁴Albert Einstein College of Medicine, Jacobi/NCB, New York, NY
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication commonly associated with autoimmune disorders. Limited treatment options are available for DAH, and time to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].